Here’s where we see the heat today:
Today we have huge movers in the tech space thanks to Oracle and RIM earnings, plus a drug breakthrough for Alkermes, JNJ’s latest take-out target, and more…

Read about the deal here.
FROM UGLY TO HORRID: Arena gets a negative vote from the FDA on its key treatment, stock collapsing, even after having already done so

Forbes has an article, 'Don't buy OREX after Arena's failure'.

See a transcript of their earnings call here.
KEY EARNINGS: Research In Motion (RIMM) pulled an 'Oracle', beating expectations atferhours and surging

Read about the completion here.

Casey's is trying to push for a higher bid from its potential acquirer. Read about it here.

Might it be due to increased analyst coverage? Not sure, read about it here.
SHORT TARGET: Chinese travel company UTA is stabilizing after being slammed by fraud allegations from Bronte Capital

We noticed some huge buying yesterday, but let us stress that we have no view on the stock, either positive or negative.
PHARMA CATALYST: Vivus (VVUS) is falling quite a bit, it might have something to do with bad news from the FDA
NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.